EU Commission reveals ‘high risk' countries for deforestation
The European Commission has published the first benchmarking list, which classifies countries according to their 'low', 'standard', or 'high' risk of deforestation.
This country classification takes into account the production of the seven commodities covered by the EU Deforestation Regulation (EUDR), including cattle, cocoa, coffee, oil palm, rubber, soya and wood.
The commission said that these commodities have been chosen 'on the basis of a thorough impact assessment identifying them as the main driver of deforestation due to agricultural expansion'.
The publication of the benchmarking list follows a positive opinion by consensus of all EU Member States, the commission added.
Deforestation
The aim of the EU Deforestation Regulation, according to the European Commission, is to ensure that goods in the EU market do not contribute to deforestation and forest degradation, both within the EU and globally.
The new regulation means that companies will only be allowed to sell products in the EU if the supplier provides a 'due diligence' statement confirming that the product does not come from deforested land or has led to forest degradation.
The regulation was set to come into effect at the end of 2024. However, this was deferred until the end of 2025, and mid-2026 for smaller businesses.
The new classification defines the extent of compliance checks that authorities in Member States' authorities have to apply for a country (1% for 'low risk', 3% for 'standard' and 9% for 'high risk').
'Sourcing from low-risk countries entails simplified due diligence obligations for operators and traders.
'Concretely, this means that they need to collect information, but not assess and mitigate risks,' the commission said.
High risk
The EU Commission confirmed that countries which are identified in the high-risk category in this first country benchmarking list are subject to sanctions from the UN Security Council or the Council of the EU on imports or exports of the relevant commodities and relevant products.
There are four countries deemed to fall into this high-risk category: Russia; Belarus; North Korea and Myanmar.
Around 140 countries, including Ireland, the other 27 EU member states, the UK and the US, have been classed as being of low-risk.
The Mercosur countries of Argentina, Brazil and Paraguay are all classed as standard-risk, while Uruguay is low-risk.
The EU Commission said that the country benchmarking will 'ensure a simple, fair and cost-efficient implementation of the EUDR'.
It claimed that the new regulation 'is already delivering positive developments on the ground to fight deforestation, climate change and biodiversity loss'.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Irish Independent
an hour ago
- Irish Independent
Farmers in EU raise alarm over Mercosur, Ukraine trade deals
French farmers urge Macron to rally EU support against Mercosur deal ©Reuters French and Spanish farmers warned on Wednesday that a flood of imports under planned European Union trade agreements with South American bloc Mercosur and Ukraine risked severely undermining European agriculture. The concerns come ahead of Brazilian President Luiz Inacio Lula da Silva's official visit to France and the expiry on Thursday of a free trade deal with Ukraine, which is expected to shift to import quotas this summer.
Agriland
3 hours ago
- Agriland
ICOS AGM: ‘Promising' developments amid uncertainty in farming
Despite high levels of uncertainty facing farming, there are 'promising political and market developments' that could support the sector in the year ahead. That's according to Edward Carr, the president of the Irish Co-operative Organisation Society (ICOS), who told the organisation's annual general meeting (AGM) yesterday (Tuesday, June 3): 'Perhaps society is finally recognising that quality food is both difficult and expensive to produce, and it must be paid for accordingly.' The AGM was held in Portlaoise, Co. Laois, in which Carr told stakeholders: 'We live in interesting times'. 'While the term 'unprecedented' is often overused, it rightly describes the challenges currently confronting co-ops and food producers.' Carr welcomed what he said were recent shifts at an EU level, saying that the 2024 European Parliament elections prompted centrist groups to 'rethink recent policies that alienated farmers'. 'The previous [European] Commission's overly purist Green Deal and dismissive attitude towards agriculture played a significant role in driving voters toward the political extremes. 'Now, we see a more balanced approach, with new agriculture and environment commissioners, Christoph Hansen and Jessika Roswall [respectively] showing early signs of being more responsive and pragmatic,' Carr said. However, he added that legal environmental commitments for farming remain in place and 'must be met'. Commenting on market conditions, he said that the prices of milk and meat are at 'unprecedented levels', supported by currently weak global supply. However, these prices are 'countered' by cost bases within the agri-sector that are constantly rising, according to Carr. 'This trend confirms what we've been saying for years. Farming has been pushed into a position where it is unattractive to younger generations. The costs are high, inflation is locked-in, the hours are long and the rewards are limited.' He also warned that global geopolitical risks, including continuing conflict, the trade impact of the current US administration under Donald Trump, and the rise of 'authoritarian voices' in Europe, could threaten stability. 'The European project, and in particular the Single Market, remains vital for Ireland's economic future. We need strong leadership to ensure that Europe continues to work for its citizens, farmers included, not just for ideological visions,' Carr commented. He also told the ICOS AGM that environmental responsibility is important, particularly in relation to the nitrates derogation. 'We've made huge strides in improving water quality, though the time lag between action and results remains frustrating. Still, the perseverance of co-ops, farmers, Teagasc, and the Department of Agriculture is beginning to bear fruit. 'Retaining the derogation is essential, not just for dairying but for the entire agri-sector,' he said. One of key issues for the year ahead, according to Carr, is the future of the Common Agricultural Policy (CAP), amid concerns that its standalone ringfenced budget could be radically overhauled. 'Agriculture and the CAP are under pressure, with serious risk that funds could be diverted to other priorities. This would be deeply damaging, not just to the basic payments scheme [Pillar I], but also to Pillar II, which is critical to delivering sustainability goals. In fact, we don't need two pillars, we need a third,' he said. 'CAP is the foundation of a sustainable and competitive farming and agri-food sector in Ireland and Europe. It plays a vital role in maintaining farm incomes, supporting rural communities and driving progress on climate and environmental goals across the EU. 'What we need is a strong, practical and fully resourced CAP; one that cuts red tape and empowers farmers to focus on producing food, not paperwork. Farming in Ireland and across the EU is struggling to attract young farmers,' Carr added. He called on the European Commission not to risk 'accelerating the generational renewal crisis'. 'Rather than potentially seeking mechanism to undermine and defund CAP, the European Commission must stand by its farming citizens, underpin food security and protect this essential policy,' he said. The ICOS president called on policymakers to 'stand firm in defence of farming', adding: 'Our sector is ready to do its part, but we need the tools and resources to do it'.
RTÉ News
3 hours ago
- RTÉ News
EU states adopt new controversial medicine regulations
EU member states have adopted a controversial set of new measures governing the regulation of medicines at European level, following two years of deadlock and "unprecedented" lobbying by the pharma sector, particularly in Ireland. The new laws will broadly reform the regulation of medicines and, critically, the issue of when to give generic drug makers access to clinical data, which tends to make certain medicines cheaper. At a meeting of EU ambassadors in Brussels this morning, the so-called pharma package received overwhelming support, with Malta registering a sole abstention. The package will now go forward for negotiation with the European Parliament. Officials say the current upheaval in the United States, where thousands of staff from the Food and Drug Administration (FDA) have been fired, and where the Trump Administration has taken a hostile attitude to science and research, prompted a large number of member states to try to get the legislation over the line. The pharma package had been deadlocked for over two years. A key sticking point has been the length of the clinical data protection period. Under existing rules, pharmaceutical companies have enjoyed an eight-year period during which rival or generic producers cannot access the clinical data related to authorised products. The provision was intended to encourage manufacturers to invest in the EU by having a guaranteed period of sole clinical data ownership. The European Commission's initial proposal was to reduce the eight years to six, on the basis that producers of generic medicines could access the data sooner, and thus produce cheaper alternatives. Under the original proposal, the patent holder could claw back two years by, for example, ensuring that trials were conducted in many member states. Ireland initially leaned in favour of the six year approach but, following intense lobbying by the pharma industry, moved toward the eight year status quo. Last month, Minister for Enterprise Peter Burke acknowledged that Ireland was shifting to the eight year protection period. He told reporters in Brussels: "We really need to have innovation in that sector, because that will give people, ultimately, access to better health care, better medicines, and ensure that we are incentivising innovation and being at the cutting edge of medical developments. "We have to get a balance between access to medicines, which is so important for citizens, but also to keep the pipeline strong so that we are at the cutting edge of innovation, and that companies have certainty as they go about developing new medicines. It is a balancing act." The Polish Presidency of the EU proposed a compromise text which would see the clinical data protection period remain at eight years. There would be a further two years where for one year the pharmaceutical company would get an extra year of market protection and a second year whereby protection would continue if they carry out more trials in member states and if they produced certain kinds of medicines for an "unmet medical need". Officials say the text provides more reassurance for generic producers and will cut timelines for authorised medicines to get to market. There are other measures, including making it easier to have multi-country and multilingual medicine packs, which should reduce production costs and make it easier to move medicines around Europe. It is understood that Ireland regards the compromise as a balance between the need to ensure pharmaceutical companies continue to innovate and invest in European research, while providing access for generic producers and ensuring the production of safe medicines. However, sources acknowledge an "unprecedented" degree of lobbying by the pharma sector, with representations being made to both the Taoiseach's and Tánaiste's offices, as well as to the Department of Health. The legislation has been deeply divisive, with member states falling into opposing camps of those wanting to promote medical research in Europe and those more concerned about cheaper drugs for patients. There are hopes that the final legislation could be adopted by the end of the year.
